Myriad Genetics Reports Increased Q1 Loss Despite Modest Revenue Growth, Reaffirms Full-Year Guidance

summarizeSummary

Myriad Genetics announced Q1 2026 financial results with a 2% revenue increase but a significantly wider GAAP net loss and negative adjusted EBITDA, while reaffirming its full-year financial guidance.

check_boxKey Events

• Increased Net Loss and Negative EBITDA

  The company reported a GAAP net loss of $34.1 million for Q1 2026, a significant increase from $0.1 million in Q1 2025. Adjusted loss per share widened to $0.09, and adjusted EBITDA was negative $4.5 million.

• Modest Revenue Growth and Cash Burn

  First-quarter 2026 revenue grew 2% year-over-year to $200.4 million. However, cash flow used in operations was $15.7 million, leading to a decrease in cash and cash equivalents to $124.4 million.

• Mixed Segment Performance

  Cancer Care Continuum revenue increased 4% and Mental Health revenue grew 24% year-over-year, driven by volume increases. Conversely, Prenatal Health revenue declined 15% due to a 12% drop in test volume.

• Key Product Development Milestones Achieved

  Myriad Genetics launched its Precise Molecular Residual Disease (MRD) assay and received FDA approval for the MyChoice CDx test as a companion diagnostic for Zejula, along with Japan MHLW approval for MyChoice CDx for prostate cancer.

auto_awesomeAnalysis

Myriad Genetics reported a significant increase in its GAAP net loss and adjusted loss per share for Q1 2026, alongside negative adjusted EBITDA and continued cash burn. While revenue saw modest year-over-year growth and key product development milestones were achieved, the worsening profitability metrics are a concern. The reaffirmation of full-year guidance implies management anticipates substantial improvements in the latter half of 2026 to meet those targets, which will be a critical area for investors to monitor.